• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The use of rituximab and bendamustine in treating chronic lymphocytic leukaemia (CLL) in end-stage renal disease (ESRD).利妥昔单抗和苯达莫司汀在终末期肾病（ESRD）患者慢性淋巴细胞白血病（CLL）治疗中的应用。
BMJ Case Rep. 2013 May 2;2013:bcr2013009637. doi: 10.1136/bcr-2013-009637.
2
Remission of a B cell CLL-associated membranoproliferative glomerulonephritis Type I with rituximab and bendamustine.利妥昔单抗联合苯达莫司汀治疗B细胞慢性淋巴细胞白血病相关的I型膜增生性肾小球肾炎缓解
Clin Nephrol. 2008 Apr;69(4):285-9. doi: 10.5414/cnp69285.
3
Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives.苯达莫司汀治疗慢性淋巴细胞白血病：结果与未来展望
Semin Oncol. 2002 Aug;29(4 Suppl 13):19-22. doi: 10.1053/sonc.2002.34875.
4
Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS).苯达莫司汀和利妥昔单抗联合治疗慢性淋巴细胞白血病相关自身免疫性溶血性贫血：法国 CLL 协作组（GCFLLC/MW 和 GOELAMS）的一项多中心回顾性研究。
Am J Hematol. 2015 Mar;90(3):204-7. doi: 10.1002/ajh.23909. Epub 2015 Jan 16.
5
Bendamustine in chronic lymphocytic leukemia: the future is combination therapy.苯达莫司汀治疗慢性淋巴细胞白血病：未来是联合疗法。
Leuk Lymphoma. 2009 Sep;50(9):1399-400. doi: 10.1080/10428190903207563.
6
Huge kidneys in a patient with chronic lymphocytic leukaemia.一名慢性淋巴细胞白血病患者的巨大肾脏。
Br J Haematol. 2015 Feb;168(4):470. doi: 10.1111/bjh.13218. Epub 2014 Nov 11.
7
[Chronic lymphocytic leukemia accompanied by renal failure].
Ter Arkh. 2014;86(12):37-41. doi: 10.17116/terarkh2014861237-41.
8
Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome.
Ann Hematol. 2001 Mar;80(3):170-3. doi: 10.1007/s002770000251.
9
Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.苯达莫司汀治疗慢性淋巴细胞白血病和利妥昔单抗难治性、惰性 B 细胞非霍奇金淋巴瘤。
Clin Ther. 2009;31 Pt 2:2290-311. doi: 10.1016/j.clinthera.2009.11.031.
10
Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma.苯达莫司汀联合利妥昔单抗治疗复发或难治性弥漫性大 B 细胞淋巴瘤。
Ann Hematol. 2014 Mar;93(3):403-9. doi: 10.1007/s00277-013-1879-x. Epub 2013 Aug 17.

引用本文的文献

1
Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review.苯达莫司汀及其在不适合接受治疗的慢性淋巴细胞白血病患者治疗中的作用：一篇综述
Ther Adv Hematol. 2017 Jun;8(6):197-205. doi: 10.1177/2040620717699365. Epub 2017 Mar 30.
2
Pharmacokinetics of gefitinib in a patient with non-small cell lung cancer undergoing continuous ambulatory peritoneal dialysis.吉非替尼在一名接受持续非卧床腹膜透析的非小细胞肺癌患者中的药代动力学。
Case Rep Oncol. 2015 Feb 11;8(1):78-82. doi: 10.1159/000375485. eCollection 2015 Jan-Apr.

本文引用的文献

1
Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study.苯达莫司汀是利妥昔单抗难治性惰性 B 细胞非霍奇金淋巴瘤患者的有效治疗方法：来自一项多中心研究的结果。
Cancer. 2010 Jan 1;116(1):106-14. doi: 10.1002/cncr.24714.
2
Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group.苯达莫司汀治疗复发或难治性慢性淋巴细胞白血病患者的疗效：德国慢性淋巴细胞白血病研究组I/II期研究结果
Haematologica. 2005 Oct;90(10):1357-64.
3
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia.利妥昔单抗治疗B细胞慢性淋巴细胞白血病患者
Blood. 2001 Sep 1;98(5):1326-31. doi: 10.1182/blood.v98.5.1326.
4
Reversible renal failure due to specific infiltration of the kidney in chronic lymphocytic leukaemia.
Nephrol Dial Transplant. 1998 Jun;13(6):1550-2. doi: 10.1093/ndt/13.6.1550.
5
Renal failure caused by leukaemic infiltration in chronic lymphocytic leukaemia.慢性淋巴细胞白血病中白血病浸润所致的肾衰竭。
J Clin Pathol. 1993 Dec;46(12):1131-3. doi: 10.1136/jcp.46.12.1131.

利妥昔单抗和苯达莫司汀在终末期肾病（ESRD）患者慢性淋巴细胞白血病（CLL）治疗中的应用。

The use of rituximab and bendamustine in treating chronic lymphocytic leukaemia (CLL) in end-stage renal disease (ESRD).

作者信息

Shoji Jun, Lew Susie Q

机构信息

Department of Medicine, George Washington University, Washington, DC, USA.

出版信息

BMJ Case Rep. 2013 May 2;2013:bcr2013009637. doi: 10.1136/bcr-2013-009637.

DOI:10.1136/bcr-2013-009637
PMID:23645657
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3669984/
Abstract

A patient with a history of type 2 diabetes mellitus and chronic lymphocytic leukaemia has renal failure with large kidneys. The patient refused kidney biopsy to determine the aetiology of her renal failure. She uses peritoneal dialysis to treat renal failure. She received rituximab and bendamustine to treat chronic lymphocytic leukaemia. Adenopathy resolves with treatment and she does not experience any electrolyte disturbances or decrease in urine output as a result of chemotherapy in the setting of renal failure. Renal function did not recover with chemotherapy.

摘要

一位患有2型糖尿病和慢性淋巴细胞白血病的患者出现肾衰竭，肾脏肿大。患者拒绝进行肾活检以确定肾衰竭的病因。她采用腹膜透析治疗肾衰竭。她接受了利妥昔单抗和苯达莫司汀治疗慢性淋巴细胞白血病。淋巴结病经治疗后消退，在肾衰竭情况下，她未因化疗出现任何电解质紊乱或尿量减少。化疗后肾功能未恢复。